324.77 USD
▲-28.55+3.90%
盘后 310.00 -0.82%
2026-08-03
市值
$9.61B
市盈率
40.77
EPS
7.96
股息率
—
52 周区间
130.50 – 382.54
成交量
534.61K
Beta
0.54
目标价
383.86
52W 低 130.5052W 高 382.54
价格走势
公司简介
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey...